Why can't I simply use a wild-type IL-2 molecule with a half-life extension?

Wild-type IL-2, even when extended, retains high affinity for IL-2Rα. This amplifies systemic toxicity and Treg expansion, drastically limiting the therapeutic dose. Our muteins provide the selective, low-toxicity core required for safe, high-dose combination therapies.

How does Creative Biolabs' approach compare to simple computational mutein designs?

Our service integrates rational computational design with rigorous experimental validation using state-of-the-art biophysical platforms like SPR and functional PBMC assays. This integrated, structure-guided approach minimizes false positives and ensures the variant is stable and functionally selective.

Selective IL-2 Receptor Binding Engineering Service

Creative Biolabs' selective IL-2 receptor binding engineering service is a comprehensive, end-to-end platform for creating next-generation cytokine therapeutics. We provide a complete workflow, from initial computational design and structure-guided mutagenesis to high-throughput library screening and full biophysical (SPR/ITC) and functional validation. Our clients gain a fully characterized, low-toxicity βγ-biased IL-2 mutein core. This de-risked asset is engineered to eliminate IL-2Rα-mediated toxicity (CLS) and is delivered optimized for seamless integration into your advanced therapeutic format - be it a tumor-targeted immunocytokine, a conditionally active prodrug, or a half-life extended conjugate.

Introduction What We Can Offer Workflow Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us

Scientific Foundation: Background on IL-2 Receptor Binding Engineering

The critical non-selective binding of wild-type IL-2 to the high-affinity IL-2Rα (CD25) subunit is the root cause of systemic toxicity (VLS/CLS) and unwanted Treg expansion. Advanced cytokine engineering overcomes this by employing structure-guided rational mutagenesis and directed evolution to create variants. These IL-2v (IL-2 variants) act as crucial, low-toxicity foundations necessary for next-generation therapeutic formats-such as PD-1 fusion proteins and prodrugs-that selectively stimulate the most critical anti-tumor CD8⁺ T cells.

To embark on the engineering phase for your next-generation IL-2 therapeutic, interested parties are encouraged to initiate a formal consultation.

What We Can Offer

Structure-Guided Design for Specific Kd Requirements

We utilize IL-2/IL-2R crystal structures to design muteins with the exact binding kinetics and βγ/α selectivity ratio your therapeutic requires. This ensures precision at the molecular level.

Low-Toxicity Core Engineered for Optimal βγ Selectivity

Our candidates virtually eliminate risks like capillary leak syndrome (CLS) by strictly avoiding the IL-2Rα binding site. We engineer a low-toxicity core proven for optimal βγ selective signaling.

End-to-End Affinity and Functional Validation

We ensure preclinical performance using rigorous biophysical tools (SPR, ITC) and functional testing on human PBMCs. This comprehensive de-risking process guarantees the quality of your lead candidate.

Modular Mutein Formats for Seamless Integration

We offer customized mutein cores optimized for seamless integration into any downstream platform. Options include fusion-ready, conditional prodrug component, or half-life extension optimized formats.

Selective IL-2 Receptor Binding Engineering Service at Creative Biolabs

Highlights

Atomic Precision Engineering

Our use of structural data allows for the rational design of amino acid mutations that precisely decouple IL-2Rα binding without compromising the crucial βγ signaling interface.

Validated Low-Toxicity Foundation

We specifically engineer against the toxicity pathway, resulting in muteins that are the ideal, low-risk basis for half-life extension (PEGylation, Fc-fusion) and conditional activation (prodrugs).

Deep Market Insight

We understand that simple βγ-bias is often insufficient for targeting PD-1⁺ exhausted T cells. We build your core to be fusion-ready, enabling the localized, targeted delivery required for maximal anti-tumor effect in combination therapies.

Unrivaled Biophysical Characterization

Our in-house SPR, ITC, and HTS platforms provide the rigorous biophysical data necessary to de-risk your candidate before preclinical investment.

Customer Reviews

FAQs

Related Services

Cell Line Development Service

We offer high-yield stable cell line generation (e.g., CHO, HEK2G) for the robust, scalable production of your final IL-2 lead candidate or fusion protein.

Learn More →

Immunocytokine Engineering Development

We optimize the flexible linker between the IL-2 mutein and the antibody. This ensures maximal structural stability and optimal bioactivity for your fusion protein in the tumor microenvironment.